Results 211 to 220 of about 59,754 (305)

Vaccination and transfusion safety at the time of expanding use of live attenuated vaccines

Vox Sanguinis, EarlyView.
Pierre Tiberghien, Pierre Gallian, Virginie de La Taille, Caroline Bacquet, Syria Laperche   +4 more
wiley   +1 more source

Beyond Extracellular Vesicle (EV) Hype: Practical Solutions and Remaining Hurdles in EV Research, Manufacturing, and Clinical Translation

Advanced Science, Volume 13, Issue 26, 8 May 2026.
ABSTRACT Extracellular vesicles (EVs) are nanoscale mediators of intercellular communication with diverse molecular cargoes that reflect their cell of origin. Advances in isolation, detection, and single‐particle analytics have revealed increasing molecular and functional heterogeneity, while exposing limitations in how EV identity and activity are ...
David J. Lundy, Zoe L. Chau, Sheng‐You Chen, Nanami Fujisawa, John J. Hill, Barnett M. Hsu, Joanne K. Liu, Karol W. Mai, James J. Lai   +8 more
wiley   +1 more source

Post-authorisation experience and reported adverse events following use of a virus-like particle chikungunya vaccine, United States and Germany, up to August 2025. [PDF]

Euro Surveill
Simone B, Lienert F.
europepmc   +1 more source

The Immune Landscape of Acral Melanoma: From Basic to Clinical

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
Lihong Jiang, Zhaotian Zhang
wiley   +1 more source

Special Issue: Vaccines and Animal Health. [PDF]

Vaccines (Basel)
Legnardi M, Tucciarone CM.
europepmc   +1 more source

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Computational Design of an mRNA Vaccine Targeting LRP6 for Triple‐Negative Breast Cancer Therapy

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Triple‐negative breast cancer (TNBC) presents a poorer prognosis than other breast cancer subtypes, attributed to its aggressive nature and the lack of specific therapeutic interventions. TNBC has high recurrence rates and limited survival despite current therapies, emphasizing the critical need for improved treatment options.
Pooriya Teimoori, Mohammadreza Heidari
wiley   +1 more source

An mRNA Vaccine Based on Antigens From Conserved Regions of Monkeypox Virus A35R and M1R With a Dimer-Like Conformation Confers Protection Against Both Monkeypox Virus and Vaccinia Virus Infections in Mice. [PDF]

MedComm (2020)
Tang C, Yuan L, Xie Y, Yang Y, Zhou Y, Wang J, Yang H, Peng R, Xu J, Yu W, Huang Q, Quan W, Li B, Wang Y, Lu S.   +14 more
europepmc   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Donor Plasmid Optimization Enhances Expression of Feline Parvovirus VP2 Protein in the Baculovirus Expression Vector System. [PDF]

Vaccines (Basel)
Meng Z, Sun Z, Li J, Qiu W, Wei J, Zhang R, Ji X, Zhu H, Yu J, Liu Y, Jiang L, Zhang J, Yu X, Zhang X.   +13 more
europepmc   +1 more source